Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2

American Journal of Clinical Pathology

Volumn 138, Issue 2, 2012, Pages 211-222

  Panarelli, Nicole C ^a   Yantiss, Rhonda K ^a   Yeh, Matthew M ^b   Liu, Yifang ^a   Chen, Yao Tseng ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cholangiocarcinoma; Colonic; Immunohistochemistry; Intestinal differentiation; Metastatic; Neuroendocrine; Pancreatobiliary

Indexed keywords

CADHERIN; CADHERIN 17; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG;

ARTICLE; BILE DUCT CARCINOMA; BLADDER CARCINOMA; CANCER GRADING; COLON ADENOCARCINOMA; ESOPHAGEAL ADENOCARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; METASTASIS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SKIN CARCINOMA; STOMACH ADENOCARCINOMA; THYROID ADENOMA; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; CADHERINS; CARCINOMA, SQUAMOUS CELL; CHOLANGIOCARCINOMA; COLONIC NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; PANCREATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84865426808     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPKSHXI3XEHW1J     Document Type: Article

References (23)

1. Greco A, Hainsworth J. Cancer of unknown primary site. In: Lawrence T, Rosemberg S, eds. Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott; 2008:2363-2387.
2. Houghton O, Connolly LE, McCluggage WG. Morules in endometrioid proliferations of the uterus and ovary consistently express the intestinal transcription factor CDX2. Histopathology. 2008;53:156-165. (Pubitemid 352032773)
3. Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27:303-310. (Pubitemid 36245795)
4. Moskaluk CA, Zhang H, Powell SM, et al. Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Mod Pathol. 2003;16:913-919. (Pubitemid 37152021)
5. Raspollini MR, Baroni G, Taddei A, et al. Primary cervical adenocarcinoma with intestinal differentiation and colonic carcinoma metastatic to cervix: an investigation using Cdx-2 and a limited immunohistochemical panel. Arch Pathol Lab Med. 2003;127:1586-1590. (Pubitemid 37517469)
6. Kim MJ. The usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray. J Korean Med Sci 2005;20:643-648.
7. Gloushankova NA. Changes in regulation of cell-cell adhesion during tumor transformation. Biochemistry (Mosc) 2008;73:742-750.
8. Makrilia N, Kollias A, Manolopoulos L, et al. Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest. 2009;27:1023-1037.
9. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene. 2008;27:6920-6929.
10. Berndorff D, Gessner R, Kreft B, et al. Liver-intestine cadherin: molecular cloning and characterization of a novel Ca(2+)-dependent cell adhesion molecule expressed in liver and intestine. J Cell Biol. 1994;125:1353-1369.
11. Angres B, Kim L, Jung R, et al. LI-cadherin gene expression during mouse intestinal development. Dev Dyn. 2001;221:182-193. (Pubitemid 32476566)
12. Hinoi T, Lucas PC, Kuick R, et al. CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia. Gastroenterology. 2002;123:1565-1577. (Pubitemid 35231656)
13. Hixson DC, McEntire KD. Detection of an altered form of cell-CAM 105 on rat transplantable and primary hepatocellular carcinomas. Cancer Res. 1989;49:6788-6794. (Pubitemid 20008823)
14. Su MC, Yuan RH, Lin CY, et al. Cadherin-17 is a useful diagnostic marker for adenocarcinomas of the digestive system. Mod Pathol. 2008;21:1379-1386.
15. Takamura M, Ichida T, Matsuda Y, et al. Reduced expression of liver-intestine cadherin is associated with progression and lymph node metastasis of human colorectal carcinoma. Cancer Lett 2004;212:253-259. (Pubitemid 38997981)
16. Takamura M, Sakamoto M, Ino Y, et al. Expression of liver-intestine cadherin and its possible interaction with galectin-3 in ductal adenocarcinoma of the pancreas. Cancer Sci. 2003;94:425-430. (Pubitemid 36790474)
17. Ito R, Oue N, Yoshida K, et al. Clinicopathological significant and prognostic influence of cadherin-17 expression in gastric cancer. Virchows Arch. 2005;447:717-722. (Pubitemid 41571187)
18. Ko S, Chu KM, Luk JM, et al. Overexpression of LI-cadherin in gastric cancer is associated with lymph node metastasis. Biochem Biophys Res Commun. 2004;319:562-568. (Pubitemid 38725983)
19. Wong BW, Luk JM, Ng IO, et al. Identification of liver-intestine cadherin in hepatocellular carcinoma: a potential disease marker. Biochem Biophys Res Commun. 2003;311:618-624. (Pubitemid 37377699)
20. Kwak JM, Min BW, Lee JH, et al. The prognostic significance of E-cadherin and liver intestine-cadherin expression in colorectal cancer. Dis Colon Rectum. 2007;50:1873-1880.
21. Motoshita J, Nakayama H, Taniyama K, et al. Molecular characteristics of differentiated-type gastric carcinoma with distinct mucin phenotype: LI-cadherin is associated with intestinal phenotype. Pathol Int 2006;56:200-205.
22. Ko S, Chu KM, Luk JM, et al. CDX2 co-localizes with liver-intestine cadherin in intestinal metaplasia and adenocarcinoma of the stomach. J Pathol. 2005;205:615-622. (Pubitemid 40514835)
23. Park SS, Kang SH, Park JM, et al. Expression of liver-intestine cadherin and its correlation with lymph node metastasis in gastric cancer: can it predict N stage preoperatively? Ann Surg Oncol. 2007;14:94-99.